Literature DB >> 28414926

Death Within 1 Month of Diagnosis in Childhood Cancer: An Analysis of Risk Factors and Scope of the Problem.

Adam L Green1, Elissa Furutani1, Karina Braga Ribeiro1, Carlos Rodriguez Galindo1.   

Abstract

Purpose Despite advances in childhood cancer care, some patients die soon after diagnosis. This population is not well described and may be under-reported. Better understanding of risk factors for early death and scope of the problem could lead to prevention of these occurrences and thus better survival rates in childhood cancer. Methods We retrieved data from SEER 13 registries on 36,337 patients age 0 to 19 years diagnosed with cancer between 1992 and 2011. Early death was defined as death within 1 month of diagnosis. Socioeconomic status data for each individual's county of residence were derived from Census 2000. Crude and adjusted odds ratios and corresponding 95% CIs were estimated for the association between early death and demographic, clinical, and socioeconomic factors. Results Percentage of early death in the period was 1.5% (n = 555). Children with acute myeloid leukemia, infant acute lymphoblastic leukemia, hepatoblastoma, and malignant brain tumors had the highest risk of early death. On multivariable analysis, an age younger than 1 year was a strong predictor of early death in all disease groups examined. Black race and Hispanic ethnicity were both risk factors for early death in multiple disease groups. Residence in counties with lower than median average income was associated with a higher risk of early death in hematologic malignancies. Percentages of early death decreased significantly over time, especially in hematologic malignancies. Conclusion Risk factors for early death in childhood cancer include an age younger than 1 year, specific diagnoses, minority race and ethnicity, and disadvantaged socioeconomic status. The population-based disease-specific percentages of early death were uniformly higher than those reported in cooperative clinical trials, suggesting that early death is under-reported in the medical literature. Initiatives to identify those at risk and develop preventive interventions should be prioritized.

Entities:  

Mesh:

Year:  2017        PMID: 28414926      PMCID: PMC5652385          DOI: 10.1200/JCO.2016.70.3249

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  20 in total

1.  Clinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference?

Authors:  Helen M Parsons; Linda C Harlan; Nita L Seibel; Jennifer L Stevens; Theresa H M Keegan
Journal:  J Clin Oncol       Date:  2011-09-19       Impact factor: 44.544

2.  Association between insurance and socioeconomic status and risk of advanced stage Hodgkin lymphoma in adolescents and young adults.

Authors:  Erlyn C Smith; Argyrios Ziogas; Hoda Anton-Culver
Journal:  Cancer       Date:  2012-06-26       Impact factor: 6.860

3.  Delays in cancer diagnosis in underinsured young adults and older adolescents.

Authors:  Sean Martin; Corinne Ulrich; Mark Munsell; Sarah Taylor; Georgia Lange; Archie Bleyer
Journal:  Oncologist       Date:  2007-07

4.  Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group.

Authors:  Wanda L Salzer; Tamekia L Jones; Meenakshi Devidas; ZoAnn E Dreyer; Lia Gore; Naomi J Winick; Lillian Sung; Elizabeth Raetz; Mignon L Loh; Cindy Y Wang; Paola De Lorenzo; Maria Grazia Valsecchi; Rob Pieters; William L Carroll; Stephen P Hunger; Joanne M Hilden; Patrick Brown
Journal:  Pediatr Blood Cancer       Date:  2014-11-18       Impact factor: 3.167

5.  Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study.

Authors:  Jeffrey S Dome; Cecilia A Cotton; Elizabeth J Perlman; Norman E Breslow; John A Kalapurakal; Michael L Ritchey; Paul E Grundy; Marcio Malogolowkin; J Bruce Beckwith; Robert C Shamberger; Gerald M Haase; Max J Coppes; Peter Coccia; Morris Kletzel; Robert M Weetman; Milton Donaldson; Roger M Macklis; Daniel M Green
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

6.  Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.

Authors:  Ursula Creutzig; Martin Zimmermann; Dirk Reinhardt; Michael Dworzak; Jan Stary; Thomas Lehrnbecher
Journal:  J Clin Oncol       Date:  2004-11-01       Impact factor: 44.544

7.  Ethnicity and age disparities in Ewing sarcoma outcome.

Authors:  Bianca Koohbanani; Gang Han; Damon Reed; Qing Zhao; Ding Yi; Evita Henderson-Jackson; Marilyn M Bui
Journal:  Fetal Pediatr Pathol       Date:  2012-10-08       Impact factor: 0.958

8.  Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group.

Authors:  Howard M Katzenstein; Kay W Chang; Mark Krailo; Zhengjia Chen; Milton J Finegold; Jon Rowland; Marleta Reynolds; Alberto Pappo; Wendy B London; Marcio Malogolowkin
Journal:  Cancer       Date:  2009-12-15       Impact factor: 6.860

9.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

10.  Comparison of Latino and non-Latino patients with Ewing sarcoma.

Authors:  Jeremy Sharib; Andrew Horvai; Florette K Gray Hazard; Heike Daldrup-Link; Robert Goldsby; Neyssa Marina; Steven G DuBois
Journal:  Pediatr Blood Cancer       Date:  2013-08-23       Impact factor: 3.167

View more
  15 in total

1.  Disparities in pediatric acute myeloid leukemia (AML) clinical trial enrollment.

Authors:  Lena E Winestone; Kelly D Getz; Pooja Rao; Yimei Li; Matt Hall; Yuan-Shung V Huang; Alix E Seif; Brian T Fisher; Richard Aplenc
Journal:  Leuk Lymphoma       Date:  2019-02-07

Review 2.  Disparities in Survival and Health Outcomes in Childhood Leukemia.

Authors:  Lena E Winestone; Richard Aplenc
Journal:  Curr Hematol Malig Rep       Date:  2019-06       Impact factor: 3.952

3.  Surgical efficacy and survival prediction of patients with unspecified malignant bone tumors.

Authors:  Shaohui He; Runyi Jiang; Haitao Sun; Jian Yang; Chen Ye; Weibo Liu; Xinghai Yang; Xiaopan Cai; Jianru Xiao
Journal:  BMC Cancer       Date:  2022-10-20       Impact factor: 4.638

4.  Impact of fluid overload and infection on respiratory adverse event development during induction therapy for childhood acute myeloid leukemia.

Authors:  Lane H Miller; Frank Keller; Ann Mertens; Mitchel Klein; Kristen Allen; Sharon Castellino; William G Woods
Journal:  Pediatr Blood Cancer       Date:  2019-09-10       Impact factor: 3.167

Review 5.  Racial and ethnic disparities among children with primary central nervous system tumors in the US.

Authors:  Edwin Nieblas-Bedolla; Briana Christophers; John R Williams; Alexandra Power-Hays; Nathalia Jimenez; Analiz Rodriguez
Journal:  J Neurooncol       Date:  2021-03-28       Impact factor: 4.130

6.  Socioeconomic disparities in survival after high-risk neuroblastoma treatment with modern therapy.

Authors:  Daniel J Zheng; Anran Li; Clement Ma; Karina B Ribeiro; Lisa Diller; Kira Bona; Jonathan M Marron
Journal:  Pediatr Blood Cancer       Date:  2021-05-22       Impact factor: 3.838

7.  Hospitalization and mortality outcomes in the first 5 years after a childhood cancer diagnosis: a population-based study.

Authors:  Angela Steineck; Eric J Chow; David R Doody; Beth A Mueller
Journal:  Cancer Causes Control       Date:  2021-04-09       Impact factor: 2.532

8.  Early death in pediatric cancer: remaining questions and next steps.

Authors:  Elissa Furutani; Carlos Rodriguez-Galindo; Adam L Green
Journal:  Oncotarget       Date:  2017-11-01

9.  Survival After Childhood Cancer-Social Inequalities in High-Income Countries.

Authors:  Hanna Mogensen; Karin Modig; Giorgio Tettamanti; Friederike Erdmann; Mats Heyman; Maria Feychting
Journal:  Front Oncol       Date:  2018-10-31       Impact factor: 6.244

10.  Global profiling of O-GlcNAcylated and/or phosphorylated proteins in hepatoblastoma.

Authors:  Hang Song; Ji Ma; Zhixuan Bian; Shuhua Chen; Jiabei Zhu; Jing Wang; Nan Huang; Minzhi Yin; Fenyong Sun; Min Xu; Qiuhui Pan
Journal:  Signal Transduct Target Ther       Date:  2019-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.